European School

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Ovarian cancer, SLS, Survival, Lymphoma, Fast track (FDA), PTCL, National Cancer Institute, CMC, Clinical trial, Committee, Research, NCI, European School, Bone marrow, AML, GPS, Pembrolizumab, Doctor of Science, Nivolumab, Safety, MRD, CDK9, BLA, Food, CR2, Zanubrutinib, Mesothelioma, BIW, MD, Completeness, WT1, FDA, DLBCL, IDMC, Therapeutic index, Type, Fast Track, Biomarker, BTK, Pharmaceutical industry

The SLS009 aza-ven treatment was well-tolerated and evoked anti-leukemic effects in 67% of patients across all levels dosed.

Key Points: 
  • The SLS009 aza-ven treatment was well-tolerated and evoked anti-leukemic effects in 67% of patients across all levels dosed.
  • The first patient who achieved a complete response continues on the study and remains leukemia-free 9 months post-enrollment.
  • The net proceeds from the offering strengthen the Company’s financial position and will be used for research and development activities, working capital, and general corporate purposes.
  • Cash Position: As of December 31, 2023, cash and cash equivalents totaled approximately $2.5 million.

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Retrieved on: 
Friday, March 1, 2024
PD, Bone marrow, AML, Toxicity, Aes, MD, Therapeutic index, European School, Conference, Safety, Biomarker, MYC, Pharmacokinetics, Patient, MRD, Survival, MD Anderson Cancer Center, Acute myeloid leukemia, CDK9, SLS, Pharmaceutical industry

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the delivery of an oral presentation of data for the cohort of patients with acute myeloid leukemia (AML) from the Phase 1 dose-escalation study of SLS009 (formerly GFH009) by Dr. Tapan Kadia, Professor at MD Anderson Cancer Center and the study’s primary investigator, at the 2024 European School of Haematology Acute Leukaemias (ESH) Conference: How to Diagnose and Treat Acute Leukaemias, taking place March 1-3, 2024, in Stockholm, Sweden.

Key Points: 
  • Positive topline data for the heavily pretreated AML patients showed evidence of anti-tumor activity increasing with higher dose levels and no significant safety issues.
  • The CR lasted eight months with the patient achieving one year survival at the latest assessment.
  • Strong inhibitory activity against key biomarkers with a dose-proportional response and universal decrease of MYC and MCL-1 in evaluable patients.
  • “Its potential strong synergy with the standard regimen of venetoclax and hypomethylating agents could open up new avenues in the treatment of acute myeloid leukemia.

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

Retrieved on: 
Thursday, February 29, 2024
University, European School, Conference, MD Anderson Cancer Center, Patient, Acute myeloid leukemia, SLS

NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the date and time for the presentation of data from the acute myeloid leukemia cohort of patients in the Phase 1 dose-escalation study of SLS009 (formerly GFH009) will be presented in an oral presentation at the 2024 European School of Haematology Acute Leukaemias (ESH) Conference: How to Diagnose and Treat Acute Leukaemias, taking place March 1-3, 2024, in Stockholm, Sweden has changed from Sunday, March 3, 2024 at 12 pm CEST to Friday March 1, 2024 at 12:55 pm CEST.

Key Points: 
  • NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the date and time for the presentation of data from the acute myeloid leukemia cohort of patients in the Phase 1 dose-escalation study of SLS009 (formerly GFH009) will be presented in an oral presentation at the 2024 European School of Haematology Acute Leukaemias (ESH) Conference: How to Diagnose and Treat Acute Leukaemias, taking place March 1-3, 2024, in Stockholm, Sweden has changed from Sunday, March 3, 2024 at 12 pm CEST to Friday March 1, 2024 at 12:55 pm CEST.
  • The presentation details are below:
    Presenter: Dr. Tapan Kadia, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas

Paratus Sciences Appoints Theresa Heah, M.D., M.B.A. as Chief Executive Officer

Retrieved on: 
Wednesday, February 21, 2024
Therapy, Ophthalmology, ESMT, Biotechnology, Aerie Pharmaceuticals, Inflammation, Management, Drug development, Bayer, Drug discovery, Polaris Partners, European School, University, Intergalactic, Disease, Applied Genetic Technologies Corporation, AAV, Human, Pharmaceutical industry

“We are thrilled to have Dr. Heah assume the helm at Paratus,” said Amir Nashat, Executive Partner of Polaris Partners, chair of Paratus’s Board of Directors and the company’s founding CEO.

Key Points: 
  • “We are thrilled to have Dr. Heah assume the helm at Paratus,” said Amir Nashat, Executive Partner of Polaris Partners, chair of Paratus’s Board of Directors and the company’s founding CEO.
  • “Theresa brings a tremendous wealth of experience as a seasoned pharma and biotech executive, having spearheaded the development and commercialization of multiple innovative therapies.
  • She most recently served as the Chief Executive Officer and President of Intergalactic Therapeutics, a non-viral gene therapy platform company.
  • Under Amir’s leadership, Paratus has made important progress advancing this premise into a state-of-the-art R&D engine.

EQS-News: Parity still a long way off / FidAR Forum 2024 calls for substantial progress in increasing the proportion of women in management positions in Germany

Retrieved on: 
Monday, February 5, 2024
Supervisory board, SAP, Financial services, CFO, Hannover Re, DAX, Regulated market, ESMT, Sustainability, Old age, SDAX, Labour, Parity, Commerzbank, Salzgitter, MDAX, Bechtle, Management, Zalando, Federation, Hope, Siemens Healthineers, European School, Woman, BASF, Property management

Berlin, 31.01.2024: DAX companies are leading the way when it comes to equal participation of women in Germany.

Key Points: 
  • Berlin, 31.01.2024: DAX companies are leading the way when it comes to equal participation of women in Germany.
  • On the supervisory boards, the proportion of women is still just below the 40 per cent mark at 38.5 per cent.
  • Six supervisory boards at Hannover Re, Zalando, Commerzbank, Covestro, Heidelberg Materials and Vonovia have at least equal representation of women and men.
  • Substantial progress requires concrete strategies for sustainably increasing the proportion of women at all management levels.

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

Retrieved on: 
Thursday, January 25, 2024
Patient, Acute myeloid leukemia, MD Anderson Cancer Center, SLS, European School, Conference, University

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that data from the acute myeloid leukemia cohort of patients in the Phase 1 dose-escalation study of SLS009 (formerly GFH009) will be presented in an oral presentation at the 2024 European School of Haematology Acute Leukaemias (ESH) Conference: 4th How to Diagnose and Treat Acute Leukaemias, taking place March 1-3, 2024, in Stockholm, Sweden.

Key Points: 
  • NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that data from the acute myeloid leukemia cohort of patients in the Phase 1 dose-escalation study of SLS009 (formerly GFH009) will be presented in an oral presentation at the 2024 European School of Haematology Acute Leukaemias (ESH) Conference: 4th How to Diagnose and Treat Acute Leukaemias, taking place March 1-3, 2024, in Stockholm, Sweden.
  • The presentation details are below:
    Presenter: Dr. Tapan Kadia, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas

Aptose Reports Results for the Third Quarter 2023

Retrieved on: 
Thursday, November 9, 2023
Apoptosis, ASH, University, Acute myeloid leukemia, APS, Patient, Poster, VEN, SYK, TUS, FLT3, ORR, KIT, CMML, Toxic leukoencephalopathy, AML, MD Anderson Cancer Center, Society, TSX, Cell, European School, Pharmaceutical industry, Airline, Venetoclax

“Investigator enthusiasm for our tuspetinib/venetoclax (TUS/VEN) doublet has led to brisk enrollment in the APTIVATE trial.

Key Points: 
  • “Investigator enthusiasm for our tuspetinib/venetoclax (TUS/VEN) doublet has led to brisk enrollment in the APTIVATE trial.
  • In the most recent data cut (October 23, 2023), the favorable safety profile remained consistent for TUS and TUS/VEN treated R/R AML patients.
  • Aptose researchers investigated the effects of TUS on key elements of the phospho-kinome and apoptotic proteome in both parental and TUS-resistant AML cells.
  • APTIVATE oral presentation at ASH 2023 by Dr.

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Retrieved on: 
Monday, October 30, 2023
APS, VEN, TUS, KIT, Acute myeloid leukemia, SYK, European School, Treatment, MD, Conference, Doctor of Philosophy, ORR, University, FLT3, Safety, International Conference on Population and Development, MD Anderson Cancer Center, Patient, TSX, AML, Response-rate ratio, SAN, Toxic leukoencephalopathy, Pharmaceutical industry, Airline, Biology

Dr. Daver is the lead investigator on Aptose’s APTIVATE trial of tuspetinib and is recognized for significant achievements in the development of novel acute myeloid leukemia (AML) treatments, including several combination therapies.

Key Points: 
  • Dr. Daver is the lead investigator on Aptose’s APTIVATE trial of tuspetinib and is recognized for significant achievements in the development of novel acute myeloid leukemia (AML) treatments, including several combination therapies.
  • Tuspetinib (TUS) is a once-daily, oral, precision targeted kinase inhibitor that suppresses select kinases that drive the proliferation of AML.
  • “We are really pleased by our growing safety and efficacy data on tuspetinib in very difficult-to-treat AML patient populations,” said Dr. Bejar.
  • “Data from the TUS/VEN doublet gives us confidence to move tuspetinib forward into a TUS/VEN/HMA triplet for the treatment of frontline newly-diagnosed AML patients.

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Retrieved on: 
Monday, October 23, 2023
VEN, TUS, Acute myeloid leukemia, European School, Treatment, MD, Conference, Abstract, SAN, Venetoclax, University, FLT3, Safety, MD Anderson Cancer Center, Patient, TSX, AML, International Conference on Learning Representations, Pharmaceutical industry, Biology

Dr. Daver is the lead investigator on Aptose’s APTIVATE trial and is recognized for significant achievements in the development of novel AML treatments, including several combination therapies.

Key Points: 
  • Dr. Daver is the lead investigator on Aptose’s APTIVATE trial and is recognized for significant achievements in the development of novel AML treatments, including several combination therapies.
  • Tuspetinib also is being studied in combination with venetoclax (VEN) in the APTIVATE international Phase 1/2 expansion trial in R/R AML patients.
  • Notably, tuspetinib targets venetoclax resistance mechanisms that may re-sensitize Prior-VEN failure patients to venetoclax.
  • Note that the poster presentations will include additional data not found in the abstracts.

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

Retrieved on: 
Monday, October 16, 2023
TSX, Abstract, TUS, International Conference on Emerging Infectious Diseases, Treatment, Trial of the century, Apoptosis, European School, AML, VEN, RSK, Acute myeloid leukemia, SAN, SYK, KIT, FLT3, Conference, Patient, Pharmaceutical industry, Biology

Aptose is planning to hold a clinical update webcast on October 30, 2023, to provide additional up-to-date data on tuspetinib.

Key Points: 
  • Aptose is planning to hold a clinical update webcast on October 30, 2023, to provide additional up-to-date data on tuspetinib.
  • The posters accepted for presentation are listed below and can be viewed beginning October 29, 2023, on site at the ESH poster exhibit hall and online on the Aptose website here .
  • Notably, TUS targets VEN resistance mechanisms and appears to re-sensitize Prior-VEN failure patients to VEN.
  • We investigated the effects of TUS on key elements of the phosphokinome and apoptotic proteome in both parental and TUS-resistant AML cells.